Department of Medicine, Alimentary Pharmabiotic Centre, Cork University Hospital, University College Cork, Clinical Sciences Building, Cork, Ireland.
Gastroenterol Clin North Am. 2011 Mar;40(1):207-22. doi: 10.1016/j.gtc.2010.12.009.
Several recent observations have raised the possibility that disturbances in the gut microbiota and/or a low-grade inflammatory state may contribute to symptomatology and the etiology of irritable bowel syndrome (IBS). Consequent on these hypotheses, several therapeutic categories have found their way into the armamentarium of those who care for IBS sufferers. These agents include probiotics, prebiotics, antibiotics, and anti-inflammatory agents.
最近有几项观察结果提出了这样一种可能性，即肠道微生物群的紊乱和/或低度炎症状态可能导致肠易激综合征（IBS）的症状和病因。基于这些假设，一些治疗类别已经成为治疗 IBS 患者的手段。这些药物包括益生菌、益生元、抗生素和抗炎药。
